Midostaurin
CAS 120685-11-2
Midostaurin (CAS 120685-11-2) is a pharmaceutical compound with 80 bioactivity targets and 96 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase |
Kd | 6.05 | - | Homo sapiens |
| Serine/threonine-protein kinase pim-1 Kinase |
Kd | 6.25 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-3 Kinase |
Kd | 6.13 | - | Homo sapiens |
| Tyrosine-protein kinase JAK3 Kinase |
Kd | 7.92 | - | Homo sapiens |
| Platelet-derived growth factor receptor beta Kinase |
Kd | 6.96 | - | Homo sapiens |
| Tyrosine-protein kinase ABL1 Kinase |
Kd | 6.1 | - | Homo sapiens |
| Mast/stem cell growth factor receptor Kit Kinase |
Kd | 8.11 | - | Homo sapiens |
| Epidermal growth factor receptor Kinase |
Kd | 8.06 | - | Homo sapiens |
| Aspartyl/asparaginyl beta-hydroxylase Enzyme |
IC50 | 5.22 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase Src Kinase |
Kd | 5.92 | - | Homo sapiens |
| Tyrosine-protein kinase Lck Kinase |
Kd | 6.55 | - | Homo sapiens |
| Tyrosine-protein kinase Yes Kinase |
Kd | 6.02 | - | Homo sapiens |
| Tyrosine-protein kinase Fyn Kinase |
Kd | 5.68 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase receptor Ret Kinase |
Kd | 7.7 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 1 Kinase |
Kd | 6.35 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 2 Kinase |
IC50 | 6.6 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 3 Kinase |
Kd | 6.17 | - | Homo sapiens |
| Macrophage colony-stimulating factor 1 receptor Kinase |
IC50 | 6.85 | - | Homo sapiens |
| Platelet-derived growth factor receptor alpha Kinase |
Kd | 6.75 | - | Homo sapiens |
| Myosin light chain kinase, smooth muscle Kinase |
Kd | 6.66 | - | Homo sapiens |
| Death-associated protein kinase 3 Kinase |
Kd | 5.75 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type 1 Kinase |
Kd | 5.7 | - | Homo sapiens |
| Mitogen-activated protein kinase 8 Kinase |
Kd | 5.36 | - | Homo sapiens |
| Fibroblast growth factor receptor 3 Kinase |
Kd | 5.77 | - | Homo sapiens |
| Rho-associated protein kinase 1 Kinase |
Kd | 5.11 | - | Homo sapiens |
| Tyrosine-protein kinase HCK Kinase |
Kd | 6.14 | - | Homo sapiens |
| Tyrosine-protein kinase JAK1 Kinase |
Kd | 6.17 | - | Homo sapiens |
| Receptor tyrosine-protein kinase erbB-4 Kinase |
Kd | 5.51 | - | Homo sapiens |
| Mitogen-activated protein kinase 10 Kinase |
Kd | 5.44 | - | Homo sapiens |
| Death-associated protein kinase 2 Kinase |
Kd | 6.05 | - | Homo sapiens |
| High affinity nerve growth factor receptor Kinase |
Kd | 6.42 | - | Homo sapiens |
| Protein kinase C delta type Kinase |
Kd | 6.5 | - | Homo sapiens |
| cAMP-dependent protein kinase catalytic subunit beta Kinase |
Kd | 6.62 | - | Homo sapiens |
| Tyrosine-protein kinase JAK2 Kinase |
Kd | 7.03 | - | Homo sapiens |
| Rho-associated protein kinase 2 Kinase |
Kd | 5.64 | - | Homo sapiens |
| Protein kinase C alpha type Kinase |
Kd | 6.14 | - | Homo sapiens |
| Tyrosine-protein kinase SYK Kinase |
Kd | 7.06 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase |
Kd | 7.44 | - | Homo sapiens |
| Tyrosine-protein kinase CSK Kinase |
Kd | 5.06 | - | Homo sapiens |
| Angiopoietin-1 receptor Kinase |
Kd | 5.72 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase |
Kd | 6.85 | - | Homo sapiens |
| AP2-associated protein kinase 1 Kinase |
Kd | 7.32 | - | Homo sapiens |
| Serine/threonine-protein kinase MARK2 Kinase |
Kd | 7 | - | Homo sapiens |
| Hepatocyte growth factor receptor Kinase |
Kd | 6.25 | - | Homo sapiens |
| Tyrosine-protein kinase Lyn Kinase |
Kd | 5.38 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-2 Kinase |
Kd | 6.62 | - | Homo sapiens |
| 5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase |
Kd | 6.75 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit beta Kinase |
Kd | 6.68 | - | Homo sapiens |
| Protein kinase C eta type Kinase |
Kd | 6.54 | - | Homo sapiens |
| Fibroblast growth factor receptor 1 Kinase |
Kd | 5.8 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Acute myeloid leukaemia recurrent | 95 | 469.066 | 10059034 |
| Febrile neutropenia | 182 | 289.771 | 10016288 |
| Bone marrow failure | 75 | 160.072 | 10065553 |
| Neutropenic colitis | 38 | 138.634 | 10062959 |
| Pancytopenia | 99 | 133.015 | 10033661 |
| Thrombocytopenia | 116 | 117.854 | 10043554 |
| Skin toxicity | 36 | 110.888 | 10059516 |
| Death | 174 | 107.214 | 10011906 |
| Tryptase increased | 19 | 98.597 | 10063342 |
| Neutropenia | 103 | 86.637 | 10029354 |
| Cytopenia | 36 | 78.55 | 10066274 |
| Sepsis | 93 | 75.649 | 10040047 |
| Septic shock | 60 | 69.947 | 10040070 |
| Lymphadenopathy | 40 | 58.625 | 10025197 |
| Pyrexia | 135 | 58.174 | 10037660 |
| Minimal residual disease | 12 | 56.423 | 10079987 |
| Malignant neoplasm progression | 55 | 51.097 | 10051398 |
| Systemic mastocytosis | 10 | 50.97 | 10042949 |
| Bacteraemia | 29 | 48.543 | 10003997 |
| Myeloblast percentage decreased | 7 | 47.708 | 10052225 |
| Diarrhoea | 153 | 47.308 | 10012735 |
| Abdominal wall wound | 8 | 47.054 | 10078479 |
| Cytomegalovirus infection reactivation | 18 | 44.883 | 10058666 |
| Nausea | 157 | 43.715 | 10028813 |
| Graft versus host disease | 21 | 41.75 | 10018651 |
| Electrocardiogram QT prolonged | 39 | 41.379 | 10014387 |
| Pneumonia | 117 | 38.595 | 10035664 |
| Bronchopulmonary aspergillosis | 19 | 31.007 | 10006473 |
| Hyperbilirubinaemia | 20 | 30.904 | 10020578 |
| Product use complaint | 11 | 30.588 | 10079400 |
| Rash maculo-papular | 25 | 28.456 | 10037868 |
| Neutropenic infection | 10 | 28.42 | 10059482 |
| Megacolon | 10 | 28.309 | 10027110 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| fms related receptor tyrosine kinase 3 FLT3 |
Inhibition | 6.28000020980835 pIC50 | 12124173 |
| fms related receptor tyrosine kinase 3 FLT3 |
Inhibition | 7.960000038146973 pKd | 22037378 |
| large tumor suppressor kinase 1 LATS1 |
Inhibition | 5.960000038146973 pKd | 19654408 |
| large tumor suppressor kinase 2 LATS2 |
Inhibition | 5.659999847412109 pKd | 19654408 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| MIDOSTAURIN | 1919083 | SU | MTHSPL |
| midostaurin | 1919083 | IN | RXNORM |
| Rydapt | 1919089 | BN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Midostaurin used for in pharmaceutical contexts?
Midostaurin (CAS 120685-11-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Midostaurin?
Midostaurin has 96 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Acute myeloid leukaemia recurrent, Febrile neutropenia, Bone marrow failure, Neutropenic colitis, Pancytopenia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Midostaurin also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Midostaurin.
What clinical phase is Midostaurin in?
No phase 1-4 clinical development badge is rendered for Midostaurin because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Midostaurin?
Midostaurin has 212 bioactivity rows in this page query. Rendered target entries include Phosphorylase b kinase gamma catalytic chain, liver/testis isoform, Serine/threonine-protein kinase pim-1, Ribosomal protein S6 kinase alpha-3, Tyrosine-protein kinase JAK3, Platelet-derived growth factor receptor beta.